← Leaderboards
Fabiana Perna
H. Lee Moffitt Cancer Ctr & Res Inst
$1,525,955
Attributed
$1,525,955
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $748K · FY2023–25$1M$750K$500K$250K$0
'23
'24
'25
Funding mix
By agency
NIH$1,525,955 · 2
By mechanism
R37$1,035,372 · 1
R21$490,583 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Gary W Reuther$4,321,756
Others in their field
Other Rising Stars on “Engineering”
- Nancy Jean Sullivan · Boston University Medical Campus$34,500,000
- Cyrus Wadia · Activate Global, Inc.$31,489,493
- Tim A Bertram · Wake Forest University School Of Medicine$30,163,580
- Rashada Alexander · American Association For The Advancement Of Science$22,676,040
- Jonathan H Elias · Association Of Universities For Research In Astronomy, Inc.$16,042,279
- Michael Hogarth · University Of California, San Diego$14,390,863
Research focus
EngineeringImmunotherapyCell Surface ProteinsEfficacy EvaluationFlow CytometryImmunotherapeutic AgentCellsCell SurfaceChimeric Antigen Receptor T CellsCombinatorialAntigensAntigen TargetingHematopoietic Stem CellsAreaAcute Myelocytic LeukemiaCell LineBiologyAntibodiesAcute Myeloid Leukemia CellChimeric Antigen ReceptorCancer CellClinical ApplicationCar T Cell TherapyIn Vitro
Grant awards (4)
Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma$507,197
R37 · FY2025 · CA · contact PI
Identifying cell surface targets for innovative immunotherapy of Multiple Myeloma$528,175
R37 · FY2024 · CA · contact PI
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy$219,800
R21 · FY2024 · CA · contact PI
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy$270,783
R21 · FY2023 · CA · contact PI